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Involvement Of Vascular 
Aldosterone Synthase In 
Phosphate-Induced Osteogenic 
Transformation Of Vascular Smooth 
Muscle Cells
Ioana Alesutan1,2,3, Jakob Voelkl1,2, Martina Feger1, Denise V. Kratschmar4, Tatsiana Castor1, 
Sobuj Mia1, Michael Sacherer5, Robert Viereck1, Oliver Borst1,6, Christina Leibrock1, Meinrad 
Gawaz6, Makoto Kuro-o7, Stefan Pilz8, Andreas Tomaschitz5,9, Alex Odermatt  4, Burkert 
Pieske2,3,10, Carsten A. Wagner  11 & Florian Lang  1
Vascular calcification resulting from hyperphosphatemia is a major determinant of mortality in 
chronic kidney disease (CKD). Vascular calcification is driven by aldosterone-sensitive osteogenic 
transformation of vascular smooth muscle cells (VSMCs). We show that even in absence of 
exogenous aldosterone, silencing and pharmacological inhibition (spironolactone, eplerenone) of the 
mineralocorticoid receptor (MR) ameliorated phosphate-induced osteo-/chondrogenic transformation 
of primary human aortic smooth muscle cells (HAoSMCs). High phosphate concentrations up-regulated 
aldosterone synthase (CYP11B2) expression in HAoSMCs. Silencing and deficiency of CYP11B2 in 
VSMCs ameliorated phosphate-induced osteogenic reprogramming and calcification. Phosphate 
treatment was followed by nuclear export of APEX1, a CYP11B2 transcriptional repressor. APEX1 
silencing up-regulated CYP11B2 expression and stimulated osteo-/chondrogenic transformation. 
APEX1 overexpression blunted the phosphate-induced osteo-/chondrogenic transformation and 
calcification of HAoSMCs. Cyp11b2 expression was higher in aortic tissue of hyperphosphatemic 
klotho-hypomorphic (kl/kl) mice than in wild-type mice. In adrenalectomized kl/kl mice, spironolactone 
treatment still significantly ameliorated aortic osteoinductive reprogramming. Our findings suggest 
that VSMCs express aldosterone synthase, which is up-regulated by phosphate-induced disruption 
of APEX1-dependent gene suppression. Vascular CYP11B2 may contribute to stimulation of VSMCs 
osteo-/chondrogenic transformation during hyperphosphatemia.
Vascular calcification with deposition of calcium-phosphate increases the risk of cardiovascular events in aging, 
diabetes and chronic kidney disease (CKD)1. Vascular calcification is therefore a powerful predictor of cardiovas-
cular and all-cause mortality2. The impaired renal phosphate elimination in CKD patients increases extracellular 
1Department of Physiology, University of Tübingen, Tübingen, Germany. 2Department of Internal Medicine and 
Cardiology, Charité University Medicine, Campus Virchow-Klinikum, Berlin, Germany. 3Berlin Institute of Health 
(BIH), Berlin, Germany. 4Department of Pharmaceutical Sciences, and the National Center for Excellence in Research 
NCCR Kidney.CH, University of Basel, Basel, Switzerland. 5Div. of Cardiology, Medical University of Graz and 
Ludwig Boltzmann Institute for Translational Heart Failure Research, Graz, Austria. 6Department of Cardiology and 
Cardiovascular Medicine, University of Tübingen, Tübingen, Germany. 7Center for Molecular Medicine, Jichi Medical 
University, Shimotsuke, Japan. 8Department of Internal Medicine, Division of Endocrinology and Metabolism, 
Medical University of Graz, Graz, Austria. 9Bad Gleichenberg Clinic, Bad Gleichenberg, Austria. 10Department of 
Cardiology, University of Graz, Graz, Austria; Department of Internal Medicine and Cardiology, German Heart Center 
Berlin (DHZB), Berlin, Germany. 11Institute of Physiology, University of Zurich, and the National Center for Excellence 
in Research NCCR Kidney, Zurich, Switzerland. Correspondence and requests for materials should be addressed to 
F.L. (email: florian.lang@uni-tuebingen.de)
Received: 25 November 2016
Accepted: 4 April 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7: 2059  | DOI:10.1038/s41598-017-01882-2
phosphate concentration, which predisposes to calcification of the medial artery layer3. Plasma phosphate levels, 
even within the normal range, are predictive of cardiovascular events, heart failure and death4, 5.
Vascular calcification is an active process, promoted by vascular smooth muscle cells (VSMCs)6. In response 
to elevated extracellular phosphate concentrations, VSMCs differentiate and undergo osteo-/chondrogenic repro-
gramming7. This reprogramming involves enhanced expression of type III sodium-dependent phosphate trans-
porter PiT1 (SLC20A1)8 and is characterized by expression of osteoblastic transcription factors Msh homeobox 
2 (MSX2) and core-binding factor alpha 1 (CBFA1, encoded by the runt-related transcription factor 2; RUNX2 
gene)9, 10. Inhibition of CBFA1 ameliorates vascular calcification11. Osteo-/chondrogenic reprogramming leads 
to expression of tissue-nonspecific alkaline phosphatase (ALPL), which hydrolyses the endogenous calcification 
inhibitor pyrophosphate, and which is therefore crucial in the formation of vascular calcification1. The mark-
ers of vascular osteo-/chondrogenic transformation are up-regulated before the onset of vascular calcification12. 
Indicators of VSMC osteo-/chondrogenic transformation are observed in vessels from human CKD patients13. 
Vessels from dialysis patients are more prone to medial calcification than vessels from healthy individuals ex vivo14. 
Therefore, the osteoinductive alterations of vascular tissue in CKD predisposes to vascular calcification14. 
However, the complex events at the onset of the signalling cascade leading to phenotypic transformation of 
VSMCs are still incompletely understood4.
VSMCs express the mineralocorticoid receptor (MR)15. Stimulation of the MR by aldosterone triggers 
osteoinductive signaling15–20 by up-regulation of PIT1 expression20, 21. The PIT1 promoter sequence har-
bours putative MR response elements and PIT1 is required for aldosterone-induced osteogenic remodelling20. 
Hyperaldosteronism may contribute to vascular calcification in hyperphosphatemic klotho-hypomorphic (kl/
kl) mice22. The hyperaldosteronism of CKD thus presumably contributes to the triggering of osteo-/chondro-
genic signaling23. Accordingly, treatment with the MR antagonist spironolactone reduces cardio-/cerebrovascular 
mortality in dialysis patients24. Further trials are being conducted to investigate the potential benefits of spirono-
lactone in CKD25, 26. The beneficial effects of spironolactone in renal disease may be independent of elevated 
circulating aldosterone levels27, 28.
Aldosterone synthesis may not be restricted to adrenal glands but aldosterone may be locally produced in 
several tissues29. Extra-adrenal steroid hormone synthesis was first reported in brain tissue30, and was later dis-
cussed for cardiac31, renal32 and vascular tissues33. Vascular cells, especially endothelial cells, are able to express 
the aldosterone synthase (also known as cytochrome P450 family 11 subfamily B member 2 or CYP11B2) and 
may therefore produce aldosterone33–35. CYP11B2 is localized to the mitochondrial inner membrane and has 
steroid 18-hydroxylase activity to synthesize aldosterone as well as 18-hydroxycorticosterone and steroid 11 
beta-hydroxylase activity36, 37. However, the physiological relevance of vascular-derived aldosterone remains con-
troversial, due to very low levels of aldosterone produced by VSMCs38. Nonetheless, in human atheroma-plaques, 
CYP11B2 expression is up-regulated39 and expression of CYP11B2 in VSMCs contributes to reactive oxygen 
species generation40. Vascular CYP11B2-dependent production of aldosterone or another yet to be identified MR 
ligand may be relevant in pathological conditions31.
The present study thus explored the possibility that vascular CYP11B2 may participate in the induction of 
osteo-/chondrogenic transformation of VSMCs.
Results
Effects of mineralocorticoid receptor blockade on phosphate-induced vascular calcification in 
vitro. To elucidate the effects of MR blockade under elevated phosphate conditions, HAoSMCs were treated 
with phosphate in the absence or presence of the MR antagonists spironolactone and eplerenone, in char-
coal-stripped FBS media. Treatment of HAoSMCs with phosphate increased calcium deposition (Fig. 1a), alkaline 
phosphatase activity (Fig. 1b) as well as PiT1 and osteogenic and chondrogenic markers CBFA1, ALPL, SOX9 and 
osterix (SP7) mRNA expression (Fig. 1c; Supplementary Fig. S1). These effects were significantly blunted in the 
presence of spironolactone or eplerenone. To further investigate the role of MR in VSMC osteo-/chondrogenic 
transformation, the MR gene (NR3C2) was silenced in HAoSMCs (Supplementary Fig. S2). PiT1, CBFA1 and 
ALPL mRNA levels were up-regulated by phosphate in negative control silenced HAoSMCs, but not in HAoSMCs 
silenced with MR siRNA (Fig. 1d). Thus, MR blockade ameliorated phosphate-induced osteo-/chondrogenic 
transformation of HAoSMCs even in the absence of exogenous aldosterone.
Regulation of aldosterone synthase expression by phosphate in VSMCs. To elucidate the under-
lying mechanisms of MR activation under high phosphate conditions, the expression of vascular CYP11B2 was 
investigated. CYP11B2 expression was detectable in HAoSMCs albeit at lower levels than in human adrenocorti-
cal carcinoma H295 cells (Supplementary Fig. S3). Cholesterol side-chain cleavage enzyme (CYP11A1), steroid 
21-hydroxylase (CYP21A2), steroidogenic acute regulatory protein (STARD1), hydroxy-delta-5-steroid dehydro-
genase, 3 beta- and steroid delta-isomerase 1 (HSD3B1), hydroxy-delta-5-steroid dehydrogenase, 3 beta- and ster-
oid delta-isomerase 2 (HSD3B2) and steroid 11-beta-hydroxylase (CYP11B1) were all expressed in HAoSMCs, 
but at lower levels as compared to H295 cells (Supplementary Figs S3 and S4). Phosphate treatment did not 
significantly modify CYP21A2, HSD3B2, STARD1 and CYP11B1 mRNA expression, but significantly increased 
CYP11A1, HSD3B1 and CYP11B2 mRNA levels in HAoSMCs (Supplementary Fig. S4, Fig. 2d). Furthermore, 
phosphate treatment did not significantly modify the mRNA expression of renin-angiotensin system components 
pro-renin receptor (ATP6AP2), angiotensin-converting enzyme (ACE) and type 1 (AGTR1) and type 2 (AGTR2) 
angiotensin II receptors in HAoSMCs (Supplementary Fig. S5).
As shown by confocal microscopy, phosphate treatment stimulated CYP11B2 protein expression in HAoSMCs 
(Fig. 2a). To confirm antibody specificity in VSMCs, MAoSMCs were isolated from aldosterone synthase-deficient 
mice (Cyp11b2−/−) and corresponding wild-type (Cyp11b2+/+) mice. Similarly, phosphate stimulated Cyp11b2 
protein expression in Cyp11b2+/+ MAoSMCs, but no expression was observed in Cyp11b2−/− MAoSMCs 
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(Fig. 2b). Increased CYP11B2 mRNA expression was paralleled by elevated CYP11B2 protein abundance in 
phosphate treated HAoSMCs (Fig. 2c,d). Angiotensin II, a known stimulator of CYP11B2 transcription, signifi-
cantly increased CYP11B2 mRNA expression to values similarly high as following phosphate treatment. CYP11B2 
mRNA levels could not be further increased by additional phosphate treatment (Supplementary Fig. S6).
Phosphate treatment did not modify MR (NR3C2) or glucocorticoid receptor (GR, NR3C1) expression in 
HAoSMCs (Supplementary Fig. S7). Most importantly, according to luciferase reporter assay in HAoSMCs, 
phosphate triggered MR response element/GR response element (MRE/GRE)-dependent transcriptional activity 
in the absence of exogenous aldosterone (Fig. 2e). Cyp11b2 mRNA expression was significantly higher in aor-
tic tissue from kl/kl mice as compared to corresponding wild-type mice (Fig. 2f) and from mice with subtotal 
nephrectomy as compared to control treated mice (Fig. 2g). Aortic expression of Cyp11b2 was further confirmed 
by qRT-PCR using intron-spanning primers (Supplementary Fig. S8a). However, aldosterone release into the 
cell culture medium was not detectable by LC-MS/MS, despite a surprisingly increased production of cortisone, 
dehydroepiandrosterone and testosterone in phosphate treated HAoSMCs (Supplementary Fig. S9).
Aldosterone synthase-dependent phosphate-induced calcification in VSMCs. Further experi-
ments were performed to investigate, whether the increased expression of CYP11B2 contributes to osteo-/chon-
drogenic reprogramming of HAoSMCs following phosphate treatment. As a result, silencing of the CYP11B2 
gene in HAoSMCs (Supplementary Fig. S10a,b) blunted the phosphate-induced MRE/GRE-dependent transcrip-
tional activity as compared to negative control silenced HAoSMCs (Supplementary Fig. S10c). The mRNA expres-
sion of the smooth muscle cell specific marker α-smooth muscle actin (ACTA2) was significantly decreased by 
phosphate treatment in negative control silenced HAoSMCs, effects ameliorated following silencing of CYP11B2 
gene (Supplementary Fig. S11a). Phosphate treatment significantly increased calcium deposition (Fig. 3a,b), alka-
line phosphatase activity (Fig. 3c) and PiT1, CBFA1 and ALPL mRNA expression (Fig. 3d) in negative control 
silenced HAoSMCs, effects ameliorated in HAoSMCs silenced with CYP11B2 siRNA. The inhibitory effects of 
CYP11B2 silencing on phosphate-induced osteo-/chondrogenic transformation of HAoSMCs were abolished by 
addition of exogenous aldosterone. Without phosphate or aldosterone treatment, silencing of CYP11B2 did not 
significantly modify the transcript levels of osteo-/chondrogenic markers in HAoSMCs (Fig. 3d).
Similar observations were made when treating MAoSMCs isolated from Cyp11b2−/− and Cyp11b2+/+ mice 
with phosphate. In control treated MAoSMCs, no significant difference on the smooth muscle cell specific marker 
Acta2 mRNA expression was noted between the genotypes. Acta2 mRNA expression was significantly decreased 
Figure 1. Mineralocorticoid receptor blockade ameliorates phosphate-induced calcification in vitro. 
Arithmetic means ± SEM of calcium content (a, n = 3; µg/mg protein), alkaline phosphatase activity (b, n = 6; 
units/mg protein) and of PIT1, CBFA1 and ALPL relative mRNA expression (c, n = 14; arbitrary units, a.u.) in 
HAoSMCs following treatment with (Pi) or without (Ctr) phosphate and with or without additional treatment 
with 10 µM spironolactone (Spr) or 10 µM eplerenone (Epl). (d) Arithmetic means ± SEM of PIT1, CBFA1 
and ALPL relative mRNA expression (n = 10; a.u.) in HAoSMCs following silencing for 48 hours with negative 
control siRNA (Neg.si.) or MR siRNA (MRsi.) without or with treatment for 24 hours with phosphate (Pi). 
*(p < 0.05), **(p < 0.01), ***(p < 0.001) statistically significant vs control treated or Neg.si. silenced HAoSMCs, 
respectively. †(p < 0.05), ††(p < 0.01), †††(p < 0.001) statistically significant vs Pi treated or Neg.si. silenced and Pi 
treated HAoSMCs, respectively.
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by phosphate treatment in Cyp11b2+/+ MAoSMCs (Supplementary Fig. S11b). Phosphate treatment increased 
the calcium deposition (Fig. 4a,b), alkaline phosphatase activity (Fig. 4c) and the mRNA expression of Cyp11b2, 
Pit1, Cbfa1 and Alpl in Cyp11b2+/+ MAoSMCs (Fig. 4d, Supplementary Fig. S8b). These effects were abrogated in 
the Cyp11b2−/− MAoSMCs. Addition of exogenous aldosterone blunted the effects of Cyp11b2 deficiency during 
phosphate treatment (Fig. 4). However, Cyp11b2−/− MAoSMCs still displayed lower alkaline phosphatase activity, 
Pit1 and Alpl mRNA expression as compared to Cyp11b2+/+ MAoSMCs during treatment with phosphate and 
exogenous aldosterone.
Role of APEX1, a transcriptional repressor of CYP11B2 in phosphate-induced VSMC calcifica-
tion. To explore the mechanisms underlying the up-regulation of CYP11B2 by phosphate, the role of APEX1 
(apurinic-apyrimidinic endonuclease 1), a transcriptional repressor of the CYP11B2 gene41, was investigated. As 
illustrated in Fig. 5a,b, phosphate treatment caused the nuclear export of APEX1 in HAoSMCs. APEX1 mRNA 
and protein expression were not significantly modified by phosphate (Supplementary Fig. S12a,b).
The functional relevance of APEX1 was further investigated by silencing of the APEX1 gene in HAoSMCs 
(Supplementary Fig. S12c). Silencing of APEX1 in HAoSMCs was followed by a significant increase of CYP11B2, 
PIT1, CBFA1 and ALPL mRNA levels to values similarly high as following treatment with phosphate (Fig. 5c). No 
additive effects of phosphate treatment and APEX1 silencing were observed. The increase of CYP11B2 expres-
sion following APEX1 silencing was not modified by additional treatment with spironolactone (Fig. 5d). In 
contrast, addition of spironolactone abrogated the increase of PIT1, CBFA1 and ALPL mRNA levels following 
APEX1 silencing, suggesting that APEX1 silencing caused spironolactone-sensitive osteogenic transformation 
via up-regulation of CYP11B2. ATF2, another transcriptional regulator of the CYP11B2 gene was apparently 
not involved in the regulation of CYP11B2 expression by phosphate, as ATF2 silencing did not prevent the 
phosphate-induced CYP11B2 mRNA expression (Supplementary Fig. S13).
Additional experiments tested whether overexpression of human APEX1 negatively regulates osteo-/chon-
drogenic transformation of HAoSMCs (Supplementary Fig. S14a). As compared to empty vector transfected 
HAoSMCs, transfection of HAoSMCs with APEX1 significantly ameliorated phosphate-induced increase of cal-
cium deposition (Fig. 6a) and alkaline phosphatase activity (Fig. 6b) and blunted the increase of CYP11B2 mRNA 
Figure 2. Phosphate induces aldosterone synthase expression in VSMCs. Representative confocal microscopy 
images showing aldosterone synthase (CYP11B2) protein expression in HAoSMCs (a) and in MAoSMCs 
isolated from aldosterone synthase-deficient mice (Cyp11b2−/−) or corresponding wild-type mice (Cyp11b2+/+)
(b) following treatment for 24 hours with (Pi) or without (Ctr) phosphate. Images are representative for four 
independent experiments. CYP11B2 expression: green labeling, nuclei: blue labeling. Scale bar: 10 μm. (c) 
Representative original Western blots and arithmetic means ± SEM (n = 4; arbitrary units, a.u.) of normalized 
CYP11B2/GAPDH protein ratio in HAoSMCs following treatment for 24 hours with (Pi) or without (Ctr) 
phosphate. Arithmetic means ± SEM of CYP11B2 relative mRNA expression (d, n = 6; a.u.) and MRE/GRE-
dependent transcriptional activity measured by luciferase reporter assay (e, n = 6; a.u.) in HAoSMCs following 
treatment for 24 hours with (Pi) or without (Ctr) phosphate. Arithmetic means ± SEM (a.u.) of Cyp11b2 relative 
mRNA expression in aortic tissue from kl/kl mice and corresponding wild-type mice (WT)(f, n = 8) and from 
DBA mice without (CTR) or with subtotal nephrectomy (Nx) (g, n = 8). *(p < 0.05) statistically significant vs. 
control treated HAoSMCs, WT mice or control treated mice, respectively.
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expression (Fig. 6c). APEX1 overexpression did not modify the calcium content or ALPL activity under control 
conditions (Supplementary Fig. S14b,c). The phosphate-induced mRNA expression of PIT1, CBFA1 and ALPL 
was blunted by APEX1 overexpression (Fig. 6c). Addition of exogenous aldosterone did not significantly modify 
CYP11B2 mRNA expression, but abrogated the effects of APEX1 overexpression on PIT1, CBFA1 and ALPL 
mRNA levels.
Effect of spironolactone and adrenalectomy on vascular osteoinductive transformation in 
klotho-hypomorphic mice. In order to estimate the in vivo significance of vascular Cyp11b2 in the early 
phase of vascular osteogenic transformation, experiments were performed in kl/kl mice and corresponding 
wild-type mice rescued by pretreatment with NH4Cl (0.28 M) added to the drinking water42. Following discontin-
uation of NH4Cl, mice were treated with either control drinking water, spironolactone in drinking water (80 mg/l) 
or adrenalectomy for 5 weeks. The NH4Cl pre-treatment abolished the strong phenotype of growth retardation of 
kl/kl mice and thereby allowed for adrenalectomy treatment (Supplementary Table S1). Plasma calcium and phos-
phate concentrations were increased in kl/kl mice irrespective of the treatments. Blood pressure was similar in all 
groups. As shown in Supplementary Fig. S15a, aortic Cyp11b2 mRNA levels were significantly higher in control 
drinking water treated kl/kl mice than in wild-type mice, but were not significantly modified by spironolactone 
treatment or adrenalectomy. Aortic Pit1, Cbfa1, Msx2, and Alpl mRNA levels were all significantly higher in con-
trol drinking water treated kl/kl mice than in wild-type mice and were significantly decreased by spironolactone 
treatment, but not significantly modified by adrenalectomy (Supplementary Fig. S15b). Similar alterations were 
observed on Cyp11b2, Cbfa1 and Msx2 protein abundance (Supplementary Fig. S15c).
Figure 3. Aldosterone synthase inhibition reduces phosphate-induced vascular calcification in vitro. (a) 
Representative original images showing Alizarin red staining in HAoSMCs silenced with negative control 
siRNA (Neg.si.) or CYP11B2 siRNA (C11B2si.) and treated with or without calcification medium and with or 
without additional treatment with 100 nM aldosterone (Aldo). Images are representative for four independent 
experiments. The calcified areas are shown as red staining. Arithmetic means ± SEM of calcium content (b, 
n = 12; µg/mg protein), alkaline phosphatase activity (c, n = 8; units/mg protein) and of PIT1, CBFA1 and ALPL 
relative mRNA expression (d, n = 14, arbitrary units, a.u.) in HAoSMCs silenced with Neg.si. or C11B2si. and 
treated with (Pi) or without (Ctr) phosphate and with or without additional treatment with 100 nM aldosterone 
(Aldo). *(p < 0.05), **(p < 0.01), ***(p < 0.001) statistically significant vs. Neg.si. silenced HAoSMCs. 
†(p < 0.05), ††(p < 0.01) statistically significant vs. Pi treated Neg.si. silenced HAoSMCs. §(p < 0.05), §§(p < 0.01), 
§§§(p < 0.001) statistically significant between Pi and Pi + Aldo treated C11B2si silenced HAoSMCs.
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A further series of experiments explored whether spironolactone influences aortic osteo-/chondrogenic trans-
formation in adrenalectomized mice (Supplementary Table S2). As illustrated in Fig. 7a, aortic Cyp11b2 transcript 
levels were significantly higher in adrenalectomized kl/kl mice than in wild-type mice irrespective of additional 
spironolactone treatment. The mRNA levels of Pit1, Cbfa1, Msx2 and Alpl were all higher in adrenalectomized 
kl/kl mice than in wild-type mice, but significantly decreased following spironolactone treatment of adrenalect-
omized kl/kl mice (Fig. 7b). Again, the effects on transcript levels were paralleled by the respective alterations of 
Cyp11b2, Cbfa1 and Msx2 protein expression (Fig. 7c).
Aldosterone synthase expression in human coronary arteries. In order to test whether CYP11B2 is 
expressed in human arteries, the expression of CYP11B2 was quantified in right coronary arteries from patients 
with impaired (IRF, n = 9) or maintained renal function (CTR, n = 10, Supplementary Table S3). Right coronary 
artery biopsies were isolated and the mRNA expression of CYP11B2 and CBFA1 was determined. In coronary 
arteries from patients with impaired renal function, log-transformed CYP11B2 mRNA expression was signif-
icantly increased as compared to patients with maintained renal function (Fig. 8a). Log-transformed CBFA1 
mRNA expression tended to be higher in vessels from patients with impaired renal function than in patients 
with maintained renal function, a difference, however, not reaching statistical significance (p = 0.054, Fig. 8b). 
CBFA1 expression was not significantly correlated with plasma aldosterone levels (Pearson correlation coefficient: 
−0.007, p = 0.978; n = 17). However, in both groups, the arterial CYP11B2 mRNA expression showed a signifi-
cant correlation with CBFA1 mRNA expression (Fig. 8c).
Discussion
The present observations suggest a novel role of vascular CYP11B2. CYP11B2 expression was up-regulated by 
elevated extracellular phosphate concentrations and CYP11B2 was required for the triggering of osteo-/chondro-
genic reprogramming of VSMCs following phosphate treatment. Vascular CYP11B2 was similarly up-regulated 
in hyperphosphatemic kl/kl mice, and in the subtotal nephrectomy renal failure mouse model. Vascular CYP11B2 
was further increased in patients with early stages of renal failure, but the results in brain dead multi organ donors 
should be interpreted with caution. Together, these findings suggest that hyperphosphatemia increases vascular 
CYP11B2 transcription, which is a prerequisite for VSMC osteo-/chondrogenic transformation.
Figure 4. Aldosterone synthase deficiency reduces phosphate-induced vascular calcification in vitro. (a) 
Representative original images showing Alizarin red staining in MAoSMCs isolated from aldosterone 
synthase-deficient mice (Cyp11b2−/−) or corresponding wild-type mice (Cyp11b2+/+) treated with or without 
calcification medium and with or without additional treatment with 100 nM aldosterone (Aldo). Images are 
representative for three independent experiments. The calcified areas are shown as red staining. Arithmetic 
means ± SEM of calcium content (b, n = 9; µg/mg protein), alkaline phosphatase activity (c, n = 8; units/mg 
protein) and of Cyp11b2, Pit1, Cbfa1 and Alpl relative mRNA expression (d, n = 9, a.u.) in MAoSMCs isolated 
from Cyp11b2−/− or Cyp11b2+/+ mice treated with (Pi) or without (Ctr) phosphate and with or without 
additional treatment with 100 nM aldosterone (Aldo). *(p < 0.05), ***(p < 0.001) statistically significant vs. 
respective control treated MAoSMCs. †(p < 0.05), ††(p < 0.01) †††(p < 0.001) statistically significant vs. respective 
wild-type MAoSMCs. §§(p < 0.01), §§§(p < 0.001) statistically significant vs. respective Pi treated MAoSMCs.
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Expression of functional CYP11B2 in the vasculature has been reported earlier33, 43. However, the signifi-
cance of vascular aldosterone production remained controversial38. As observed in this study, VSMCs express 
enzymes involved in the generation of aldosterone precursors from cholesterol and therefore may be able to 
produce aldosterone de novo. Human pulmonary artery endothelial cells express CYP11B2 and were described to 
synthesize aldosterone during hypoxia33. In these cells, hypoxia did not affect CYP11B2 expression, but increased 
vascular aldosterone synthesis by up-regulation of StAR (encoded by STARD1 gene) expression, which facili-
tates the first and rate-limiting step in aldosterone biosynthesis33. In VSMCs, phosphate treatment did not affect 
StAR expression, but up-regulated CYP11B2, suggesting that hypoxia and phosphate exposure act via differ-
ent mechanisms on the vascular aldosterone producing system. Phosphate treatment increased production and 
release of glucocorticoids and androgens by VSMCs, but aldosterone could not be detected. Aldosterone secreted 
by VSMCs may be at low levels not detectable by the employed method or remain and act intracellularly. Low 
aldosterone levels within the VSMCs may be sufficient for MR activation. Furthermore, vascular CYP11B2 may 
rather produce 18-hydroxycorticosterone, which was not included in our protocol. A profound effect of vascular 
CYP11B2 on aldosterone levels may also require precursors from the circulation. Nevertheless, CYP11B2 silenc-
ing blunted phosphate-induced MR-dependent transcriptional activity, suggesting that MR activation is, at least 
partly, dependent on CYP11B2 up-regulation. In accordance, functional effects of CYP11B2 in the vasculature 
have been reported44, 45 and appear important especially during pathological conditions.
A potential significance of vascular auto/paracrine MR activation is underscored by the inhibitory effect of 
the MR blocker spironolactone on aortic osteo-/chondrogenic transformation in adrenalectomized kl/kl mice. 
At least in those mice, local aldosterone synthesis rather than adrenal aldosterone release appears to be instru-
mental for VSMCs osteoinduction. MR-independent effects of spironolactone cannot be ruled out46, but the 
effects of spironolactone and eplerenone were mimicked by MR silencing in vitro, an observation confirming 
a crucial role for MR activation in vascular calcification. However, a ligand-independent transactivation or 
Figure 5. APEX1 represses aldosterone synthase expression in HAoSMCs. (a) Representative confocal 
microscopy images of APEX1 protein expression in HAoSMCs following treatment for 24 hours with (Pi) or 
without (Ctr) phosphate. Images are representative for four independent experiments. APEX1 expression: 
green labeling, nuclei: blue labeling. Scale bar: 10 μm. (b) Representative original Western blots and arithmetic 
means ± SEM (n = 5; arbitrary units, a.u.) of normalized nuclear to cytoplasmic APEX1 protein ratio 
normalized to HDAC2 and α-Tubulin protein in the nuclear fraction and cytoplasmic fraction respectively, 
in HAoSMCs following treatment for 24 hours with (Pi) or without (Ctr) phosphate. *(p < 0.05) statistically 
significant vs. control treated HAoSMCs. Arithmetic means ± SEM (a.u.) of CYP11B2, PIT1, CBFA1 and ALPL 
relative mRNA expression in HAoSMCs silenced for 48 hours with negative control siRNA (Neg.si.) or APEX1 
siRNA (APEX1si.) and treated for 24 hours with (Pi) or without (Ctr) phosphate (c, n = 8) or with or without 
10 µM spironolactone (Spr) (d, n = 6). *(p < 0.05), **(p < 0.01), ***(p < 0.001) statistically significant vs. Neg.
si. silenced HAoSMCs. †(p < 0.05) statistically significant vs. APEX1si. silenced HAoSMCs.
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glucocorticoid-dependent activation of the MR could contribute to the observed effects47. Glucocorticoids are 
able to activate MR and promote vascular calcification47. The effects of androgens on vascular calcification are still 
controversial. Androgens may induce vascular calcification through androgen receptor (AR) activation48, but may 
also have anti-calcifying effects by AR-dependent up-regulation of Gas6 transcription49.
Up-regulation of vascular CYP11B2 has also been demonstrated in vascular tissue of diabetic rats34. 
Vasculo-protective properties have further been associated with spironolactone in diabetes models50. It is there-
fore tempting to speculate, that vascular CYP11B2 could also contribute to osteoinductive remodeling of vascular 
tissue during diabetes.
The present observations further shed light on the mechanism underlying the effect of extracellular phosphate 
on increased CYP11B2 expression. Elevated phosphate triggered the nuclear export of the transcriptional repres-
sor APEX1, which has been shown to repress CYP11B2 mRNA expression41. The transcription factor ATF2, a 
positive regulator of CYP11B2 gene expression was apparently not involved in the up-regulation of CYP11B2 by 
phosphate41. APEX1 silencing up-regulated CYP11B2 mRNA expression and mimicked the effects of phosphate 
in HAoSMCs. Conversely, APEX1 overexpression ameliorated the phosphate-induced HAoSMCs osteo-/chon-
drogenic transformation. APEX1 is thus a key factor in VSMCs CYP11B2 expression. Nuclear export of APEX1 
has previously been shown following nitrosative stress, which was also suggested to participate in the regulation 
of vascular calcification51, 52. APEX1 exported from the nucleus is further triggered by the histone deacetylase 
inhibitor trichostatin-A53, which promotes VSMC calcification via up-regulation of alkaline phosphatase54.
VSMCs have previously been shown to express the MR55 and MR activation has been shown to augment 
vascular calcification via direct up-regulation of PiT1 gene expression15–17. In view of the present and previous 
observations, the following sequence of events may lead to vascular calcification: Hyperphosphatemia leads to 
down-regulation of nuclear APEX1, which is in turn followed by up-regulation of CYP11B2, MR activation, 
MR-dependent up-regulation of PIT1 and subsequent triggering of osteogenic transformation. According to the 
present observations, the protective effects of MR blockade on osteoinductive signaling in VSMCs may be, at least 
in part, independent of elevated circulating aldosterone levels.
First clinical trials indicate that spironolactone treatment reduces morbidity and mortality in hemodialysis 
patients24. MR inhibition may lead to transient reduction of renal function and hyperkalemia, but is in gen-
eral well tolerated in CKD patients24, 56. In CKD patients, elevated aldosterone levels were observed, increasing 
Figure 6. APEX1 overexpression ameliorates phosphate-induced vascular calcification in vitro. Arithmetic 
means ± SEM of calcium content (a, n = 8; µg/mg protein), alkaline phosphatase activity (b, n = 8; units/mg 
protein) and of CYP11B2, PIT1, CBFA1 and ALPL relative mRNA expression (c, n = 8; a.u.) in HAoSMCs 
transfected with empty vector (V) or APEX1 (AX1) and treated with (Pi) or without (Ctr) phosphate and with 
or without additional treatment with 100 nM aldosterone (Aldo). *(p < 0.05), **(p < 0.01), ***(p < 0.001) 
statistically significant vs vector transfected HAoSMCs. †(p < 0.05) statistically significant vs Pi treated vector 
transfected HAoSMCs. §§(p < 0.01), §§§(p < 0.001) statistically significant between Pi and Pi + Aldo treated 
APEX1 transfected HAoSMCs.
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with advanced renal insufficiency23. Vascular CYP11B2 expression is triggered by an increase of extracellular 
phosphate concentration via an APEX1-dependent mechanism and is decisive for the triggering of osteo-/chon-
drogenic reprogramming of VSMCs during elevated phosphate conditions. The present observations therefore 
advocate the therapeutic use of MR blockade in conditions with hyperphosphatemia such as CKD even in the 
absence of hyperaldosteronism.
Figure 7. Vascular osteoinductive transformation in adrenalectomized kl/kl mice is ameliorated by 
spironolactone. Arithmetic means ± SEM (n = 10–11; arbitrary units, a.u) of aortic Cyp11b2 (a) and Pit1, Cbfa1, 
Msx2 and Alpl (b) relative mRNA expression in wild-type (WT) and kl/kl mice following discontinuation 
of dietary rescue and treatment without or with spironolactone (Spr) and adrenalectomy (Adx) for 5 weeks. 
*(p < 0.05), **(p < 0.01), ***(p < 0.001) statistically significant vs. WT control mice. †(p < 0.05), ††(p < 0.01) 
statistically significant between kl/kl-Adx and kl/kl-Adx + Spr. (c) Representative confocal microscopy 
images showing Cyp11b2, Cbfa1 and Msx2 protein expression in aortic tissues from wild-type (WT) and kl/
kl mice following discontinuation of dietary rescue and treatment without or with spironolactone (Spr) and 
adrenalectomy (Adx) for 5 weeks. Images are representative of four mice per group. Protein expression: green 
labeling; nuclei: blue labeling and actin staining: red labeling. Scale bar: 20 µm.
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Methods
Cell culture of VSMCs. Primary human aortic smooth muscle cells (HAoSMCs; Thermo Fisher Scientific) 
were cultured in Waymouth’s MB 752/1 medium and Ham’s F-12 nutrient mixture (1:1, Thermo Fisher Scientific) 
supplemented with 10% FBS (Thermo Fisher Scientific) and 100 U/ml penicillin and 100 µg/ml streptomycin 
(Thermo Fisher Scientific). HAoSMCs were grown to confluency and used from passages 4 to 11 (n indicates 
number of independent experiments performed at different passages of the cells). At least 6 different batches of 
HAoSMCs were used during the course of this study and each experiment was performed in at least 2 different 
batches of HAoSMCs depending on the availability of the cells.
Primary mouse aortic smooth muscle cells (MAoSMCs) were isolated from aldosterone synthase-deficient 
or corresponding wild-type mice57. VSMCs were obtained from pooled aortic tissue by a modification of the 
protocol described by Owens et al.58. Animals were sacrificed and the thoracic aorta from below the arch to the 
proximity of the diaphragm was removed and placed in Hanks’ balanced salt solution (HBSS, Thermo Fischer 
Scientific). The fat and fibrous tissue around the aorta was removed. The aortic tissue was then incubated for 
10 minutes at 37 °C, 5% CO2 in HBSS enzyme solution containing 125 U/ml collagenase type II (Worthington 
Biochemical), 0.744 U/ml elastase (Sigma Aldrich), 1 mg/ml soybean trypsin inhibitor (Sigma Aldrich), 100 U/ml 
penicillin and 100 µg/ml streptomycin. The adventitia was removed and the luminal surface scraped with forceps 
to remove endothelial cells. The aortic tissue was then cut into 1 mm pieces and incubated in HBSS enzyme solu-
tion for the final digestion for another 2 hours at 37 °C, 5% CO2 with trituration every 30 minutes. The resulting 
cell suspension was centrifuged at 1200 rpm for 1 minute and washed with DMEM/F12 medium (Thermo Fisher 
Scientific) supplemented with 20% FBS and 100 U/ml penicillin and 100 µg/ml streptomycin. The cells were sus-
pended in cell culture medium and transferred into 48-well plates leaving them undisturbed for 7 days. The media 
was then replaced every 2–3 days. From passage 2, MAoSMCs were grown to confluence in DMEM/F12 medium 
supplemented with 10% FBS and 100 U/ml penicillin and 100 µg/ml streptomycin and used for experiments from 
passages 3 to 5. N indicates the number of independent experiments performed at different passages of the cells 
from three independent MAoSMCs preparations.
Figure 8. Aldosterone synthase and CBFA1 expression in human coronary arteries. Boxplots of log-
transformed CYP11B2 (a, arbitrary units, a.u.) and CBFA1 (b, a.u.) relative mRNA expression in right coronary 
artery tissue from patients with maintained (CTR, n = 10) and impaired (IRF, n = 9) renal function. (c) 
Association of log-transformed CYP11B2 (a.u.) and CBFA1 (a.u.) relative mRNA expression in right coronary 
artery tissue from patients with maintained (n = 10) and impaired (n = 9) renal function. P values are indicated 
in the figure.
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The media was changed to 10% charcoal-stripped FBS media (Sigma Aldrich) 24 hours prior to each exper-
iment to reduce the effects of endogenous ligands. For silencing experiments, HAoSMCs were transfected with 
10 nM MR siRNA (ID no. s8839), 10 nM CYP11B2 siRNA (ID no. s3869), 10 nM APEX1 siRNA (ID no. s1445), 
10 nM ATF2 siRNA (ID no. s3493) or 10 nM negative control siRNA (ID no. 4390843)(Ambion, Thermo Fisher 
Scientific) using the siPORT amine transfection agent (Ambion, Thermo Fisher Scientific) according to the man-
ufacturer’s protocol. HAoSMCs were transfected with 2 µg DNA encoding human APEX1 (Source BioScience 
LifeSciences) in pCMV-SPORT6 or with empty pCMV-SPORT6 vector as control using X-tremeGENE HP DNA 
transfection reagent (Roche Applied Science) according to the manufacturer’s protocol. Silencing and transfection 
efficiency were verified by qRT-PCR. Unless indicated otherwise, VSMCs were treated for 24 hours (for qRT-PCR, 
WB, Luciferase assay) or 7 days (for ALPL activity assay) with 2 mM β-glycerophosphate (Sigma-Aldrich) and 
with 100 nM aldosterone, 100 nM angiotensin II, 10 µM spironolactone or 10 µM eplerenone (stock dissolved 
in DMSO, Sigma-Aldrich). Equal amounts of vehicle were used as control. Treatment for 14 days with 3 mM 
sodium phosphate buffer (Sigma-Aldrich) or for 10 days with 10 mM β-glycerophosphate and 1.5 mM CaCl2 
(Sigma-Aldrich) were used as calcification media for the calcium content measurements or Alizarin Red staining, 
respectively59. Fresh media with agents were added every 2–3 days.
Culture of H295 cells. Human adrenocortical carcinoma H295 cells (kindly provided by Prof. Dr. F. 
Beuschlein, Medizinische Klinik und Poliklinik IV, Munich, Germany) were routinely cultured in DMEM/F12 
medium (Thermo Fisher Scientific) supplemented with 1% ITS + premix (BD Biosciences), 2.5% Nu-serum (BD 
Biosciences) and 100 U/ml penicillin and 100 µg/ml streptomycin (Thermo Fisher Scientific).
Animal experiments. All animal experiments were conducted according to the guidelines of the American 
Physiological Society as well as the German law for the welfare of animals and were approved by local authori-
ties (Regierungspräsidium Tübingen). The origin and background of aldosterone synthase-deficient mice and of 
klotho-hypomorphic (kl/kl) mice was described previously57, 60, 61. Kl/kl and corresponding wild-type (WT) mice 
without rescue diet treatment were sacrificed and aortic tissue snap frozen in liquid nitrogen. To allow for surgi-
cal intervention, kl/kl mice and WT mice were fed with NH4Cl (0.28 M, Sigma-Aldrich) added to the drinking 
water for phenotypical rescue42. The drinking solution was discontinued and male mice were randomized into 
treatment groups of control drinking water or spironolactone containing drinking water (80 mg/l, Sigma-Aldrich) 
at the age of 5–6 weeks. Where indicated, bilateral adrenalectomy was surgically performed under isoflurane 
anaesthesia. Analgesia was performed by subcutaneous injection of buprenorphin (0.05 mg/kg BW). All adre-
nalectomized mice received 0.9% NaCl in either control drinking water or spironolactone containing drinking 
water. Blood pressure was assessed from tail cuff measurements before the end of the observational period. After 
5 weeks of treatment, animals were sacrificed, blood was obtained by retro-orbital puncture and murine tissues 
snap frozen in liquid nitrogen or fixed in 4% paraformaldehyde. The plasma phosphate and calcium concentra-
tions were determined utilizing a photometric method (FUJI FDC 3500i, Sysmex). The subtotal nephrectomy in 
mice was described previously62.
Calcium content. VSMCs were decalcified for 24 hours at 4 °C in 0.6 M HCl. Calcium content was deter-
mined colorimetrically using QuantiChrom Calcium assay kit (BioAssay Systems) according to the manufactur-
er’s protocol. VSMCs were lysed with 0.1 M NaOH/0.1% SDS. Calcium content was normalized to total protein 
concentration as assessed by the Bradford assay (Bio-Rad Laboratories). To visualize calcium deposition, VSMCs 
were fixed with 4% paraformaldehyde and stained with 2% Alizarin Red (pH4.5). The calcified areas are shown 
as red staining.
Alkaline phosphatase (ALPL) activity assay. VSMCs were washed with PBS and assayed for ALPL 
activity using the ALPL colorimetric assay kit (Abcam) according to the manufacturer’s protocol. ALPL activity 
was normalized to total protein concentration as assessed by the Bradford assay (Bio-Rad Laboratories).
Luciferase assay. HAoSMCs were transfected for 48 hours with 1 µg DNA mixture of MRE/GRE-responsive 
luciferase construct and a constitutively expressing Renilla construct (40:1 ratio, Qiagen) using X-tremeGENE HP 
DNA transfection reagent (Roche Applied Science) according to the manufacturer’s protocol. Renilla-Luciferase 
served as control for transfection efficiency. HAoSMCs were silenced and/or treated as indicated. After the 
incubation period, cells were washed with PBS, lysed with Passive Lysis Buffer (Promega) and assayed for tran-
scriptional activity using Dual-Luciferase Reporter Assay (Promega) and a luminometer (Walter Wallac 2 plate 
reader, Perkin Elmer) according to the manufacturer’s protocol. All results are expressed as the ratio of MRE/
GRE Firefly-Luciferase to Renilla-Luciferase (relative light units) normalized to Neg.si silenced or control treated 
HAoSMCs.
Steroid quantification. After the incubation period, the cell culture medium was stored at −80 °C. Steroid 
hormone levels [cortisol, cortisone, corticosterone, 11-dehydrocorticosterone, 11-deoxycorticosterone, aldoster-
one, dehydroepiandrosterone (DHEA), androstene-3,17-dione and testosterone] were determined as described 
previously with minor adaptations63. Briefly, for solid-phase extraction, each cell culture supernatant (4 mL) 
was mixed with protein precipitation solution (0.8 M zinc sulphate in water/methanol; 50/50, v/v, 1 mL) that 
contained deuterium-labeled aldosterone, corticosterone, androstenedione, and testosterone as internal stand-
ards (ISTD). Samples were incubated in a thermoshaker by thoroughly shaking (10 min at 4 °C, 1000 rotations/
min). The samples were centrifuged (10 min at 4 °C, 3184 × g). The supernatants were transferred to Oasis HBL 
SPE cartridges (Waters, 60 mg), preconditioned with methanol and water. After washing twice with water (3 ml) 
and twice with methanol/water (3 ml, 10/90, v/v), the steroids were eluted with methanol (3 mL) and evapo-
rated to dryness (35 °C). The samples were reconstituted in methanol (50 µL). All steroids were separated and 
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quantified by ultra-pressure LC-MS/MS (UPLC-MS/MS) using an Agilent 1290 UPLC coupled to an Agilent 
6490 triple quadrupole mass spectrometer equipped with a jet-stream electrospray ionization interface (Agilent 
Technologies). Analyte separation was achieved using a reverse-phase column (1.7 µm, 150 mm; Acquity UPLC 
BEH C18; Waters). MASSHUNTER software (Agilent Technologies) was used for data acquisition and analysis. 
The accuracy was between 85% and 115% for all analytes.
Quantitative RT-PCR. Quantitative RT-PCR was performed as described20. Total RNA was isolated from 
mouse tissue and VSMCs by using Trifast Reagent (Peqlab) according to the manufacturer’s instructions. Reverse 
transcription of 2 µg RNA was performed using oligo(dT)12–18 primers (Thermo Fisher Scientific) and SuperScript 
III Reverse Transcriptase (Thermo Fisher Scientific). Quantitative RT-PCR was performed with the iCycler iQTM 
Real-Time PCR Detection System (Bio-Rad Laboratories) and iQTM Sybr Green Supermix (Bio-Rad Laboratories) 
according to the manufacturer’s instructions. A detailed description of the primers is available in the supplemen-
tary material. The specificity of the PCR products was confirmed by analysis of the melting curves. All PCRs were 
performed in duplicate and relative mRNA fold changes were calculated by the 2−ΔΔCt method using Gapdh as 
internal reference.
Extraction of nuclear and cytoplasmic proteins. The preparation of cytoplasmic and nuclear extracts 
from HAoSMCs was performed using the NE-PER nuclear and cytoplasmic extraction reagents (Thermo Fisher 
Scientific) according to the manufacturer’s instructions. Protein concentration was determined by Bradford assay 
(Biorad Laboratories).
Western blot analysis. After washing with PBS, HAoSMCs were lysed with ice-cold IP lysis buffer (Thermo 
Fisher Scientific) supplemented with complete protease and phosphatase inhibitor cocktail (Thermo Fisher 
Scientific). After centrifugation at 10000 rpm for 5 min, the proteins were boiled in Roti-Load1 Buffer (Carl Roth 
GmbH) at 100 °C for 10 min. Proteins were separated on SDS-polyacrylamide gels and transferred to PVDF 
membranes. The membranes were incubated overnight at 4 °C with primary antibodies: rabbit anti-CYP11B2 
(diluted 1:1000, Abcam), goat anti-APEX1 (diluted 1:500, Santa Cruz Biotechnology), rabbit anti-HDAC2, rab-
bit anti-α-Tubulin or rabbit anti-GAPDH antibody (diluted 1:1000, Cell Signaling) and then with secondary 
anti-goat HRP-conjugated (diluted 1:1000, Santa Cruz Biotechnology) or anti-rabbit HRP-conjugated antibody 
(diluted 1:1000, Cell Signaling) for 1 hour at RT. For loading controls, the membranes were stripped in stripping 
buffer (Thermo Fisher Scientific) at RT for 10 min. Antibody binding was detected with ECL detection reagent 
(Thermo Fisher Scientific). Bands were quantified with Quantity One Software (Bio-Rad Laboratories).
Confocal microscopy. For immunohistochemistry, 4% paraformaldehyde-fixed murine thoracic aortic tis-
sues were cryoprotected in 30% sucrose, frozen in mounting medium (Tissue-Tek, Sakura Finetek) and sectioned 
at a thickness of 8 µm on coated slides. For immunostaining, sections were dehydrated at RT for 30 min and fixed 
in 100% methanol for 10 min at RT. For immunocytochemistry, VSMCs cultured onto four-well chamber slides 
(BD Biostatus) were fixed with 4% paraformaldehyde/PBS for 15 min at RT and permeabilized with ice-cold 
100% methanol for 10 min at RT. To reduce non-specific background staining, slides were incubated with 5% 
normal goat serum or with 5% BSA in PBS/ 0.1% Triton-X100 for 1 hour at RT. Sections were incubated overnight 
at 4 °C with primary antibodies: goat polyclonal anti-Cyp11b2, goat polyclonal anti-APEX1, rabbit polyclonal 
anti-Cbfa1 or goat polyclonal anti-Msx2 (diluted 1:50, Santa Cruz Biotechnology). Binding of primary antibodies 
was visualised using goat anti-rabbit Alexa488-conjugated antibody or donkey anti-goat Alexa488-conjugated 
antibody (diluted 1:1000, Thermo Fisher Scientific) incubated for 1 hour at RT. Nuclei were stained using DRAQ5 
dye (diluted 1:1000, Biostatus) and actin using Rhodamine Phalloidin (diluted 1:100, Thermo Fisher Scientific). 
The slides were mounted with Prolong Gold antifade reagent (Thermo Fisher Scientific). Images were collected 
with a confocal laser-scanning microscope (LSM 510, Carl Zeiss MicroImaging GmbH) using a water immersion 
A-Plan 40x/1.2 W DICIII or A-Plan × 63/1.2 W. Confocal images are representative for four mice per group or 
four independent experiments, respectively. Negative controls were carried out simultaneously with all experi-
ments by omitting incubation with primary antibodies.
Human coronary arteries. The procedure was approved by the Ethical Committee of the Medical University 
of Graz (ref. No: 26-355-ex13/14) and was carried out in accordance with the Declaration of Helsinki. Coronary 
biopsies were obtained from brain dead multi organ donors where hearts were not suitable for transplantation 
(Supplementary Table S4, n = 19). Biopsies were transferred in Custodiol® Solution, (Dr. Franz Köhler Chemie 
GmbH) and subsequently dissected and immediately snap frozen in liquid nitrogen. Serum and plasma samples 
were centrifuged at 4 °C with 3000 rpm, aliquoted and snap frozen in liquid nitrogen. From 2 patients, no serum 
or plasma samples were obtainable. Samples were separated in two groups according to renal function as assessed 
by plasma creatinine levels. Creatinine levels below 1.1 (mg/dl) were defined as normal renal function (CTR, 
n = 10) at the time of assessment. The impaired renal function (IRF) group (n = 9) had elevated plasma creatinine 
(mean = 2.0 ± 0.2 mg/dl) levels. Aldosterone was measured in plasma using an ELISA kit (Alpha Diagnostics 
International) according to the manufacturer’s protocol. Plasma aldosterone levels (CTR: 222 ± 31 pg/ml; IRF: 
303 ± 43 pg/ml, n = 8–9) or plasma phosphate levels (CTR: 3.2 ± 0.5 mg/dl; IRF: 4.0 ± 0.4 mg/dl, n = 8–9) did not 
differ significantly between the groups. However, due to the sample origin from brain dead multi organ donors 
these measurements should be interpreted with caution.
Statistics. Data are shown as arithmetic mean ± SEM unless indicated otherwise. N indicates the num-
ber of independent experiments performed at different passages of the cells or the number of mice examined, 
respectively. Normality was tested with Shapiro-Wilk test. Non-normal datasets were transformed (log, recip-
rocal or sqrt) prior to statistical testing to provide normality according to Shapiro-Wilk test. Statistical testing 
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was performed by one-way Anova followed by Tukey-test for homoscedastic data or Games-Howell test for 
heteroscedastic data. Non-normal data was tested by the Steel-Dwass method. Two groups were compared by 
unpaired two-tailed t-test. Results from human coronary arteries are shown as box-plots or scatter-plot of the 
log-transformed relative mRNA expression. For correlation analysis, Pearson correlation test was performed. 
p < 0.05 was considered statistically significant.
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